<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndromes</z:e> (CAPS) are a group of inherited <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> consisting of familial cold-induced autoinflammatory syndrome (FCAS), <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> (MWS), and <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>; also known as <z:hpo ids='HP_0011010'>chronic</z:hpo> infantile neurologic, cutaneous, articular [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>] syndrome) </plain></SENT>
<SENT sid="1" pm="."><plain>These <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disorders</z:e> are associated with heterozygous mutations in the NLRP3 (CIAS1) gene, which encodes the protein NALP3 or cryopyrin, and <z:mp ids='MP_0001845'>inflammation</z:mp> driven by excessive production of the cytokine interleukin-1beta (IL-1beta) </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011034'>Amyloidosis</z:hpo> is a serious complication with 25% of MWS patients developing <z:hpo ids='HP_0011034'>amyloidosis</z:hpo>, with occasional fatal consequences, whilst up to 20% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e> patients die from various complications, before reaching the early adulthood </plain></SENT>
<SENT sid="3" pm="."><plain>In some <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CINCA</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e> adult survivors <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> can also occur </plain></SENT>
<SENT sid="4" pm="."><plain>Prior to the discovery of the CIAS1 gene mutations and the advent of IL-1 targeted therapy, treatment was aimed at suppressing <z:mp ids='MP_0001845'>inflammation</z:mp>, with limited success </plain></SENT>
<SENT sid="5" pm="."><plain>The selective blockade of IL-1beta, with anakinra (IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>), not only provided supportive evidence for the role of IL-1beta in CAPS, but also demonstrated the efficacy of targeting IL-1beta for treatment of these conditions </plain></SENT>
<SENT sid="6" pm="."><plain>In February, 2008, 'Orphan Drug' approval from the Food and Drug Administration (FDA) for rilonacept (IL-1 Trap/Arcalyst(), Regeneron Pharmaceuticals, Inc) was given for the treatment of two CAPS disorders, FCAS and MWS in adults and children 12 years and older, making rilonacept the first therapy approved for the treatment of CAPS </plain></SENT>
</text></document>